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Background: TAT-RasGAP317–326 is a Ras GTPase-activating protein (RasGAP)-derived peptide that requires deleted in
liver cancer-1 (DLC1) for its antimetastatic activities.
Results: AWXWmotif within TAT-RasGAP317–326 mediates RasGAP-DLC1 interaction.
Conclusion: The tryptophan residues of TAT-RasGAP317–326 are crucial for its activity
Significance: The WXWmotif could be used to design anticancer small molecules bearing TAT-RasGAP317–326 activities.
TAT-RasGAP317–326, a cell-permeable 10-amino acid-long
peptide derived from the N2 fragment of p120 Ras GTPase-ac-
tivating protein (RasGAP), sensitizes tumor cells to apoptosis
induced by various anticancer therapies. This RasGAP-derived
peptide, by targeting the deleted in liver cancer-1 (DLC1) tumor
suppressor, also hampers cell migration and invasion by pro-
moting cell adherence and by inhibiting cell movement. Here,
we systematically investigated the role of each amino acidwithin
the RasGAP317–326 sequence for the anticancer activities of
TAT-RasGAP317–326. We report here that the first three amino
acids of this sequence, tryptophan, methionine, and tryptophan
(WMW), are necessary and sufficient to sensitize cancer cells to
cisplatin-induced apoptosis and to reduce cell migration. The
WMWmotif was found to be critical for the binding of fragment
N2 to DLC1. These results define the interactionmode between
the active anticancer sequence of RasGAP and DLC1. This
knowledge will facilitate the design of small molecules bearing
the tumor-sensitizing and antimetastatic activities of TAT-
RasGAP317–326.
Cancer is the second leading cause of death worldwide (1).
Ninety percent of cancer-related death is attributed to metas-
tases (1). Surgery, chemotherapy, and radiotherapy remain at
present the main clinical therapeutic tools to treat cancer.
These treatments are very efficacious against some cancers but
are of limited long term efficacy against others. Besides devel-
oping new anticancer modalities, increasing the efficacy of cur-
rent therapies is of clear and timely interest.
p120 Ras GTPase-activating protein (from now on referred
to as RasGAP)2 is amultidomain protein. It was first reported as
a negative modulator of the Ras signaling pathway (2). This
activity requires the GAP domain of the protein (2). It was
found later that other domains of the protein had signaling
activities that were not related to its function as a GAP. For
example, the N-terminal moiety of RasGAP can positively reg-
ulate MAP kinase kinases such as Ras and Mos (3). RasGAP is
also a specific caspase-3 substrate (4). Because of the presence
of two sites within RasGAP that have differential sensitivities
toward caspase-3-mediated cleavage, the RasGAP/caspase-3
module acts as a stress sensor in cells (5). In the presence of low
stresses, caspase-3 is mildly activated, and this leads to the par-
tial cleavage of RasGAP into anN-terminal fragment that exerts
potent, Akt-dependent, antiapoptotic activities (4, 6, 7). When
cells are subjected to strong stresses, RasGAP is fully processed
by caspase-3, further cleaving the N-terminal fragment and
henceforth destroying its ability to protect cells.
One of the fragments generated by the full cleavage of Ras-
GAP by caspase-3, fragment N2 (RasGAP158–455), has the
capacity to increase the sensitivity to anticancer treatments of
various tumor cell lines, both in vitro and in vivo (6, 8). Similarly
to fragment N2, a cell-permeable 10-amino acid peptide con-
tained within the SH3 domain of fragment N2, called TAT-
RasGAP317–326, was found to efficiently sensitize cancer cells to
anticancer agent-induced apoptosis (9) and to inhibit tumor
growth when combined with chemotherapy (8). We recently
reported that fragmentN2was an efficient inhibitor of themet-
astatic cascade (10). TAT-RasGAP317–326 also inhibited cell
migration and invasion into basement membrane matrix by
strengthening adhesiveness of the cells to their substratum (11).
However, in an attempt to use TAT-RasGAP317–326 as an anti-
metastatic tool, we found, using mouse models, that this pep-
tide was not always delivered efficiently to tumors (10). This
delivery issue would call for the development of small mole-
cules bearing the activity of RasGAP317–326. However, such
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developmentwould greatly benefit fromabetter understanding
of the mode of action of TAT-RasGAP317–326.
Actin cytoskeleton dynamics controls adhesion, migration,
and invasion and is mainly regulated by the small GTPases of
the Rho family (e.g. Rho itself, Rac, and Cdc42 (12, 13)). We
found that the TAT-RasGAP317–326 molecular properties by
which it induces adhesion and inhibits migration rely on mod-
ulation of the actin cytoskeleton and requires deleted in liver
cancer-1 (DLC1), a RhoGAP that functions as a tumor and
metastasis suppressor (11, 14). Therefore, understanding
whether and howTAT-RasGAP317–326 engages DLC1 is of cru-
cial interest.
Although peptide therapeutics are gathering increasing
interest for the treatment of tumors (15), classical issues asso-
ciated with peptide-based therapy are impeding their develop-
ment. These issues consist of the rapid clearance from the body,
the lack of targetable ability, their short half-lives, and their
expensive production costs. Consistent with this, the Lipinski’s
rule-of-five, a model that predicts the likeliness of a compound
to be translated into an orally active drug, is of bad prognosis for
peptide development (16).
The goal of the present study was to characterize the impor-
tance of each of the RasGAP317–326 amino acids for its sensitiz-
ing activity and its ability to increase cell adhesiveness. This was
performed to better understand the mode of action of the pep-
tide and to gather structure-function information that could be
used for pharmacological development to facilitate the devel-
opment of a small molecule that mimics TAT-RasGAP317–326.
Our recent finding that fragmentN2 requires DLC1 for its anti-
metastatic activities prompted us to dissect how these twomol-
ecules interact. Here, we report the exact binding mode
between DLC1 and TAT-RasGAP317–326 and we identify a
shortWXWmotif located at the N-terminal end of the peptide
that carries its anticancer activities.
EXPERIMENTAL PROCEDURES
Cell Lines and Cell Culture—The osteosarcoma cell line used
in this study is U2OS (ATCC; HTB-96). HEK-293T cells were
used for protein interaction studies as reported previously (11).
The cells were cultured at 37 °C and 5% CO2 and were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM)
(Gibco; 61965) supplemented with 10% fetal bovine serum
(FBS) (Gibco; 10270) for not more than 2 months and were
constantly checked for their morphology.
Peptide Synthesis—The peptides used in this study were
made of D-amino acids, which provide resistance to proteases
and therefore increase their stability. In order for the side chains
to be similarly exposed as in L-form peptides (8), the D-form pep-
tides were synthesized starting with the last C-terminal residue
(retro-inversopeptides).TheTAT-RasGAP317–326 (GRKKRRQR-
RRGGWMWVTNLRTD), the TAT (HIV-TAT48–57) (GRK-
KRRQRRR), and all the peptides mentioned in the figures were
synthesized at theDepartmentofBiochemistry,University ofLau-
sanne, Switzerland using the Fmoc (N-(9-fluorenyl)methoxycar-
bonyl) technology, purified by HPLC, and tested by mass spec-
trometry as reported earlier (9). Two glycine residues were
inserted as a linker between TAT and the peptides of interest.
Trypsin-mediated Detachment Assays, Transfection, Immuno-
precipitation, and Western Blotting—Trypsin-mediated detach-
ment assays, Giemsa staining, calcium-phosphate transfection,
immunoprecipitation, andWestern blottingwere performed as
reported previously (11). The primary antibodies used were
anti-HA (Covance; MMS-101r), anti-V5 (Invitrogen; 46-1157)
and anti-GFP (Clontech; 632380).
Wound-healing Scratch Assay—Five hundred thousand
U2OSwere grown in 3.5-cmplates. The day after, the cells were
pretreated as indicated in the figures for 3 h. Awound in the cell
layer was made with a tip (0.4-mm diameter at its extremity).
Five pictures per wound were taken just after wounding (0 h),
and then 24 and 48 h after wounding (the same five fields per
wound were photographed at each time point). Wound areas
were measured using the ImageJ software. The migration area
was calculated by subtracting the 48 h value by the 0 h value,
and the data were normalized against the untreated condition.
For time-course experiments, the data obtained after 24 h were
treated similarly than for 48 h.
Apoptosis Measurements—One hundred and fifty thousand
U2OS cells were grown in 3.5-cm plates. The day after, the cells
were treated for 22 h with 20 M TAT-coupled peptides in the
presence or in the absence of 30 M cisplatin (Sigma-Aldrich;
P4394) as indicated in the figures. The cells were then fixed, and
the nuclei were stained in 2% paraformaldehyde containing 10
g/ml Hoechst 33342 (Molecular Probes; H1399) for 15 min.
The pyknotic nuclei were visualized using the Nikon Eclipse
TS100 microscope equipped with fluorescence; they were then
scored and reported in percentage over total number of cells.
Greyscale Heat Map—Heat map was performed by semi-
quantitative evaluation of the effects of the alanine-substituted
peptides as compared with wild-type 317–326 peptide. The
results onwhich the heatmap is based appear in Fig. 1B (adher-
ence; 20Mvalues), Fig. 2A (migration), and Fig. 2B (apoptosis).
This heat map is a greyscaled representation of whether the
alanine-substituted peptides recapitulate the effects of 317–
326. Specifically for apoptosis, theminimal effect (in black) was
set to the “cisplatin alone” condition, and themaximal effect (in
white) was set to the “cisplatin  317–326” condition; for
adherence, the minimal effect (in black) was set to the
“untreated  trypsin” condition, and the maximal effect (in
white) was set to the “317–326 trypsin” condition; for migra-
tion, the minimal effect (in white) was set to the “317–326”
condition, and the maximal effect (in black) was set to the
“untreated” condition.
Plasmids—The extension .dn3 indicates that the backbone
plasmid is pcDNA3 (plasmid 1) from Invitrogen. The Stag-HA-
hRasGAP[158–455].dn3 (plasmid 644) (here called HA-N2),
Stag-HA-hRasGAP[158–455](W317A).dn3 (plasmid 793)
(here called HA-N2 (W317A)), and V5-mDLC1[1–1092].dn3
(plasmid 791) (here called V5-DLC1) plasmids were described
earlier (11). The Stag-HA-hRasGAP[158–455](W319A).dn3
(plasmid 803) (here calledHA-N2 (W319A)) plasmid encodes a
Stag- and HA-tagged form of fragment N2 bearing a mutation
of tryptophan 319 into an alanine residue (W319A). The tem-
plate vector used for starting the mutagenesis is the HA-N2
plasmid. Mutagenesis was performed using the mega-primer
procedure (17) as follows. (i) TheW319Amutation was gener-
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ated by PCR amplification of HA-N2 using oligonucleotide
(oligo) 1019 (human RasGAP nucleotides 1052–1097 (NCBI
entryM23379) except for nucleotides (underlined) that create a
W319A mutation and a silent mutation generating a Bsu36I
restriction site: (GAA TTA GAA GAT GGA TGG ATG GCG
(W319A)GTTACAAACC (N1-N2of Bsu36I) TAAGG (N7of
Bsu36I) ACAGATG)) and oligo 62 (TACCTAGCATGAACA-
GATTG (random sequence) AGGGGCAAACAACAGATG
(pcDNA3 nucleotides 1080–1063)). (ii) The PCR product
obtained in (i) was purified and elongated on the HA-N2 tem-
plate. (iii) The PCR reaction was resumed after the addition of
oligo 28 and oligo 70. The PCR in (iii) was digested with BsiWI
and NotI and ligated into plasmid HA-N2 digested with the
same enzymes. The DLC1 mutant plasmids were generated
using the same methodology. The V5-mDLC1[1–1092]
(R677A).dn3 (plasmid 804) (here called V5-DLC1 (R677A))
plasmid encodes a V5-tagged form of theMus musculus DLC1
transcript variant 2 (NM_015802.3) bearing a mutation of argi-
nine 677 into an alanine residue (R677A). The template vector
used for starting the mutagenesis is the V5-DLC1 plasmid.
Mutagenesis was performed as follows. (i) TheR677Amutation
was generated by PCR amplification of V5-DLC1 using oligo
1016 (mouse Dlc1 nucleotides 2368–2411 (NCBI entry
NM_015802.3) except for nucleotides (underlined) that create
a R677A mutation and a silent mutation generating an EcoRI
restriction site: (GTC GGG CTC TTC GCG (R677A) AAG
TCA GGT GTC AAA TCC CG A (N2 of EcoRI) AT T (N5 of
EcoRI) CAGGCT) and oligo 62. (ii) The PCR product obtained
in (i) was purified and elongated on the V5-DLC1 template. (iii)
The PCR reaction was resumed after the addition of oligo 28
(TAATACGACTCACTATAGGGAGA (pcDNA3 sequence
863–885)) and oligo 70 (TACCTAGCATGAACAGATTG
(same random sequence as in nucleotide oligo 62)). The PCR in
(iii) was digestedwith EcoRV andXhoI and ligated into plasmid
V5-DLC1 digestedwith the same enzymes. TheV5-mDLC1[1–
1092](N829A,L830A).dn3 (plasmid 805) (here called V5-DLC1
(N829A,L830A)) plasmid encodes a V5-tagged form of the
M. musculus DLC1 transcript variant 2 (NM_015802.3) bear-
ing a mutation of asparagine 829 and leucine 830 into alanine
residues (N829A,L830A). The template vector used for starting
the mutagenesis is the V5-DLC1. Mutagenesis was performed as
follows. (i) The N829A and L830A mutations were generated by
PCR amplification of V5-DLC1 using oligo 1017 (mouse Dlc1
nucleotides 2821–2859 (NCBI entry NM_015802.3) except for
nucleotides (underlined) that create theN829A and L830Amuta-
tions and a newNotI restriction site: (AAAGACCTGAATGAA
GCGGCC (N829A,L830A and (N1–6) of NotI) GCGGCGACT
CAAGGGCTG) and oligo 62). (ii) The PCR product obtained in
(i) was purified and elongated on the V5-DLC1 template. (iii) The
PCR reaction was resumed after the addition of oligo 28 and oligo
70. The PCR in (iii) was digested with EcoRI and XhoI and ligated
into plasmid V5-DLC1 digested with the same enzymes. The
extension .gfp indicates that the backbone plasmid is pEGFP-C1
(plasmid 6) fromClontech and encodes the green fluorescent pro-
tein. The pEGFP-hDLC1.gfp (plasmid 811) (here called GFP-
DLC1),pEGFP-hDLC2.gfp (plasmid812) (herecalledGFP-DLC2)
and pEGFP-hDLC3.gfp (plasmid 813) (here called GFP-DLC3)
plasmids encode GFP-tagged versions of human DLC1, DLC2,
and DLC3, respectively, and were described earlier (18, 19).
The extension .pgx indicates that the backbone plasmid is
pGEX-4T-1 from GE Healthcare. GST-hDLC1[625–878].pgx
(plasmid 816) (here called GST-DLC1-GAP) is an expression
vector encoding the GST fusion human DLC1 GAP domain
corresponding to nucleotide 1873–2634 of the human DLC1
gene (GenBank: AAK97501.1).
In Silico Prediction of Protein Interaction—The rigid docking
of p120 RasGAP to DLC1 was performed using the PatchDock
web server (20, 21), version beta 1.3, with the default complex
type and a 4.0 Å clustering root mean square deviation. The
DLC1 GAP domain (Protein Data Bank (PDB) ID: 3KUQ (22,
23)) was used as the receptor and the RasGAP SH3 domain
(PDB ID: 2J05 (24)) as the ligand. The receptor and ligand bind-
ing sites were not imposed, and no additional constraint was
applied during the docking. The best-scored calculated binding
mode was retained for structural analysis.
Recombinant Protein Production and Isothermal Titration
Calorimetry—RecombinantGST-DLC1-GAPdomainwas pro-
duced as reported previously using BL21 transformed with the
GST-GAP-DLC1.pgx construct (25). Elution of the GST-
DLC1-GAP domain in 30 mM reduced L-glutathione (Sigma-
Aldrich, G4251, in 50 mM Tris (pH:7.4), 100 mM NaCl) was
followed by 2 h of dialysis in 4 liters of PBS. The dialysis buffer
was then used as titration buffer and to resuspend TAT-
RasGAP317–326 and the corresponding tryptophan mutants.
Isothermal titration calorimetry was performed as reported
previously using the ITC200 system (GE Healthcare Life Sci-
ences) unless otherwise mentioned (26). The sample cell (200
l) was loadedwith 50MGST-DLC1-GAP, whereas the TAT-
RasGAP317–326 and the tryptophanmutant concentrations in the
syringe were 500 M. The titration experiment started with an
injection of 0.5l followed by 15 injections of 2.49l, each lasting
5 s, with a 3-min interval between each injection. Controls and
measurements were performed as reported earlier (26).
Statistical Analysis—All experiments were performed inde-
pendently. The results were expressed as mean  95% confi-
dence intervals. One-way ANOVAs and repeated measure-
ment ANOVAs were performed using the R software (version
2.11.0) and were followed by a Tukey test for multiple compar-
isons. Asterisks denote statistically significant differences (p
value 0.05).
RESULTS
The individual contribution of each amino acid of the Ras-
GAP 317–326 sequence was evaluated through an alanine-
scanning approach. This approach has been successfully used
to identify several protein-protein interactions (27). For exam-
ple, it has been employed to map the binding between the
human immunodeficiency virus (HIV)GP120 glycoprotein and
the human CD4 receptor (28). This methodology consists of
substituting amino acids of interest into alanine residues (27).
Alanine that has a methyl side chain is considered as neutral
and, in contrast to glycine that is also a small amino acid with
only a hydrogen side chain, prevents introduction of conforma-
tional flexibility. Alanine substitutions therefore tend to keep
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intact the overall secondary structure of the investigated pro-
tein (27).
We first evaluated the consequence of these mutations on
adhesion induced by TAT-RasGAP317–326 (from now on
referred to as 317–326). Alanine substitutions of the trypto-
phan residues at positions 317 and 319 abrogated the capacity
of the peptide to increase cell adherence (Fig. 1, A and B). Sub-
stitutions at positions 318, 320, 323, 324, and 325 strongly
reduced the pro-adherence activity of 317–326, but some resid-
ual adherence was nevertheless observed. Replacement of
amino acids 321, 322, and 326 had no or only limited effect on
the ability of the peptide to increase cell adherence. These
results indicate that the tryptophan and leucine residues of
317–326 are critically required for the pro-adhesion activity of
the peptide. Residues 318, 320, and 324–325 are also important
for this activity but do not appear as indispensable as the tryp-
tophan residues because their replacement does not totally
abolish the activity of 317–326. One could therefore generate a
consensus sequence for RasGAP317–326-mediated adhesion
increase, WMWVXXLRTX, where the X represents residues
that are not required for this activity and where the bold resi-
dues are those that seem the most important for the pro-adhe-
sive activity of the peptide. Interestingly, this consensus
sequence is almost identical to the amino acids that are con-
served between vertebrates and insects in the RasGAP 317–326
sequence (WXWVTXXRTX) (Fig. 1C). Hence the data pre-
sented in Fig. 1 indicate that most evolutionary conserved
amino acids are important for the increase cell adherencemedi-
ated by the 317–326 sequence of RasGAP.
We next assessed whether the amino acids identified to be
required for the pro-adhesion activity of 317–326 were also
playing a role in the capacity of the peptide to inhibit migration
and to sensitize tumor cells to genotoxins. Similarly to the
adhesion increase, alanine substitutions of the Trp-317, Trp-
319, Leu-323, Arg-324, and Thr-325 amino acids completely or
partially abrogated the capacity of 317–326 to inhibit cell
migration (Fig. 2A) or to favor cell death induced by cisplatin, a
commonly used chemotherapeutic agent (Fig. 2B). The Met-
318 and Val-320 residues seem, however, to be differentially
required for 317–326-mediated effects on apoptosis, adhesion,
and migration (Fig. 2C). This differential requirement of Met-
318 and Val-320 could be the consequence of 317–326mediat-
ing its effects on apoptosis, adhesion, and migration via differ-
ent signaling pathways. Alternatively, this could be explained
by a difference in the sensitivity of the assays used to measure
apoptosis, adhesion, and migration and/or a difference in the
sensitivity of these biological processes themselves. We there-
fore performed a dose response with 317–326 and measured
apoptosis sensitization, adhesion increase, and migration inhi-
bition. Fig. 2D shows that these three assays or biological pro-
cesses do not display similar sensitivities to the RasGAP-de-
rived peptide. Indeed, the EC50 for apoptosis sensitization (5
M)was lower than the EC50 for adhesion promotion (11.5M),
whichwas lower than the EC50 formigration (16.5M). In other
words, less 317–326 is required to render tumor cells more
sensitive to cisplatin-induced apoptosis than is required to
mediate increased adhesiveness and even less so to inhibit cell
migration. This indicates that a decrease in the activity of the
peptide will first impact on its capacity to inhibit migration,
then on its ability to increase cell adherence, and lastly on its
capacity to sensitize cells to anticancer treatments. Hence a
mutation that partially affects the activity of 317–326 should
have a stronger impact on migration inhibition than on cell
adherence promotion and tumor sensitization. This is particu-
larly obvious with the V320A mutation. This can also be seen
somewhat with the M318A and L323A mutations. Therefore,
these results are not contradictory with the possibility that
modulation of apoptosis, adhesion, and migration by 317–326
is the consequence of one protein ormolecule being targeted by
the peptide.
If the twoN-terminal tryptophan residues of 317–326 are the
only crucial residues for the activity of the peptide, it should be
possible to shorten the 317–326 sequence without losing its
activity. Hence, truncated versions of 317–326 were analyzed
for their effects on adhesion, migration, and sensitization to
apoptosis. Fig. 3,A and B, show that 317–323 and 317–321 still
induce increased adherence, although to a lower extent than
the parental 317–326 peptide. In contrast, 322–326 failed to
augment cell adhesiveness. This indicates that the 317–321
sequence is sufficient to increase cell adherence. Although the
322–326 sequence lacked activity, it still may be required for
optimal 317–326 activity as revealed by the point mutations
within this sequence (Figs. 1 and 2). It was reported that the
322–326 sequence participates in the formation of a -sheet
required for dimerization of the RasGAP SH3 domains. One
could therefore hypothesize that the 322–326 fulfills structural
functions to constrain the 317–321 stretch in a conformation
that is optimal for its activity. Co-incubation of 317–321 and
322–326 failed to potentiate 317–321-induced adhesion, indi-
cating that both domains have to be carried by the same entity
to be physiologically fully active. When the active peptides are
narrowed down to four (317–320) and three (317–319) amino
acids, their pro-adhesive property is even more decreased (Fig.
3B). We also tested the ability of the truncated peptides to
inhibit migration (Fig. 3C) and to sensitize to cisplatin-induced
apoptosis (Fig. 3D). The slight 317–323-mediated increase of
adherence was translated into a weak but statistically signifi-
cant inhibition of migration, whereas smaller peptides did not
affect migration or affected it to a much lesser extent (Fig. 3C).
On the other hand, the apoptosis-sensitizing effect of the trun-
cated versions, including the 317–319 tripeptide, was similar to
the one induced by the full-length peptide (Fig. 3D). Of note,
theDrosophila peptide that carries a leucine residue at position
318 was highly efficient in recapitulating the effects of the
human version (Fig. 3, A–D). Altogether, these results indicate
that the WXW motif within the 317–326 sequence carries the
anticancer activities of the peptide.
To better understand why the 317–319 tripeptide sensi-
tizes tumor cells to apoptosis but does not recapitulate the
effects on adhesion and more importantly on migration, we
evaluated the effects of increased dose of 317–319 on migra-
tion. Wound closure was measured over a 48-h period to
have a longer window for the evaluation of migration
dynamics. At a 40 M concentration, the 317–319 tripeptide
significantly inhibited migration (Fig. 4A). When the 317–
319 concentration increased to 60 M, the effect on migra-
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tion was not stronger than with 40 M, indicating that 40 M
is already a saturating dose and that 317–319 cannot reach
the inhibitory effect obtained with the full-length peptide. In
contrast, the dose-response experiment depicted in Fig. 4B
shows that 317–319 is as efficient as 317–326 in sensitizing
tumor cells to cisplatin-induced apoptosis. This finding may
indicate that two different molecules are targeted by 317–
326 to mediate inhibition of migration and to sensitize
tumor cells to death.
The DLC family consists of three isoforms (DLC1, DLC2,
and DLC3) with nonredundant activity (14). DLC1 regulates
cell migration (29). DLC2 couldmodulate apoptosis as it can be
localized at the mitochondria level (30). Fragment N2, the
parental polypeptide from which 317–326 is derived, can bind
FIGURE 1. Cell adherence induced by alanine-substituted RasGAP317–326 peptides. A and B, U2OS cells were cultured overnight and then treated for 8 h
with 20 M TAT or 20 M of the indicated TAT-coupled peptides or left untreated. The cells were then subjected to trypsin-mediated detachment assays. The
images shown in panel A correspond to 20 M peptide-treated cells (n 4 independent experiments). Scale bar: 200 M for all images. w/o trypsin, without
trypsin. B, dose-response quantitation (n 4 independent experiments). C, alignment of the p120 RasGAP317–326 sequences fromdifferent species. The amino
acids conserved during evolution are shaded in gray. Drosoph., Drosophila.
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DLC1 (11) but whether fragment N2 also binds the other DLC
isoformswas not investigated. Fig. 4C shows thatDLC2, but not
DLC3, interacts with fragment N2. As fragment N2 binds both
DLC1 and DLC2, this raises the possibility that 317–326 mod-
ulates adhesion/migration through DLC1 and apoptosis
through DLC2 (model 1 in Fig. 4D). Another possibility would
be that DLC1 and DLC2 are both required for the effects on
adhesion/migration and that a still unidentified protein medi-
ates the apoptotic response (model 2 in Fig. 4D). Jaiswal et al.
(31) have shown that the SH3 domain of RasGAP binds to the
DLC1 GAP domain using isothermal titration calorimetry
(ITC). However, whether 317–326 directly binds DLC proteins
FIGURE 2. Ability of alanine-substituted RasGAP317–326 peptides to inhibit cell migration and sensitize cancer cells against cisplatin-induced
apoptosis. A, U2OS cells were grown to confluence and were pretreated for 3 h with 20 M of the indicated TAT-coupled peptides. The cells were then
subjected to wound healing scratch assays. The graph displays the percentage of migration over untreated cells. Asterisks and number signs denote
statistical significant differences after one-way ANOVA (asterisk: different from untreated condition; number sign: different from 317–326 treatment; n
7 independent experiments). Error bars indicatemean 95% confidence intervals. B, U2OS cells were cultured overnight andwere subsequently treated
for 22 h with 20 M of the indicated TAT-coupled peptides in the presence or in the absence of 30 M cisplatin. The number of pyknotic nuclei was then
scored and reported as the percentage of apoptosis. The light gray region displays the level of apoptosis induced by cisplatin alone, and the dark gray
region shows the apoptosis sensitization zone. Asterisks and number signs denote statistical significant differences after one-way ANOVA with the
cisplatin-only treatment and with the cisplatin  317–326 treatment, respectively (n  6 independent experiments). Error bars indicate mean  95%
confidence intervals, C, schematic representation of the importance of each amino acid within the wild-type sequence for the apoptosis sensitization,
adhesion promotion, and migration inhibition processes. D, comparison of the dose-dependent effect of 317–326 on apoptosis sensitization, adhesion
(prevention of detachment), and inhibition of migration. Each experiment was performed as described in earlier figures and panels except that here all
the responses are reported as the percentage of the maximum observed effect. Error bars indicate mean 95% confidence intervals.
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has not been reported. We used ITC to assess this point. ITC
records temperature changes generated when two molecules
interact (32). Repeated injection of 317–326 into the cell con-
taining the DLC1 GAP domain led to a marked variation in
temperature (endergonic reaction) that was progressively
reduced with subsequent 317–326 injections (indicative of
binding site saturation and hence the specificity of the interac-
tion) (Fig. 4E, upper panel). In contrast, injections of the two
tryptophan peptide mutants (W317A andW319A) in the incu-
bation cell of the ITC device containing theDLC1GAP domain
induced minimal temperature changes (these changes are
caused by the injection of a given volume in the cell) (Fig. 4F).
FIGURE3.Ability of truncatedandvariantRasGAP317–326peptides to increaseadherence, inhibit cellmigration, and sensitize cancer cells to cisplatin-
induced apoptosis. A, sequences of the peptides tested. Residues shaded in gray are those that are found required for adhesion based on the alanine-
scanningperformed in Fig. 1. The residues inwhiteon a black background are those that differ from the residues shaded in gray.Droso,Drosophila. B, U2OS cells
were culturedovernight andwere subsequently treated for 8 hwith 20MTATor 20Mof the indicated TAT-coupledpeptides or left untreated. The cellswere
then subjected to trypsin-mediated detachment assays. Error bars indicatemean 95% confidence intervals, C, U2OS cells were subjected to wound-healing
scratch assays in the presence of 20 M of the indicated TAT-coupled peptides. Asterisks and number signs denote statistical significant differences after
one-way ANOVA from the untreated condition and from the 317–326 treatment, respectively (n 7 independent experiments). Error bars indicate mean
95% confidence intervals,D, U2OS cells were cultured overnight andwere subsequently treated for 22 h with 20M of the indicated TAT-coupled peptides in
the presence or in the absence of 30M cisplatin. The number of pyknotic nuclei was then scored and reported as the percentage of apoptosis. The light gray
regiondisplays the level of apoptosis inducedby cisplatin alone, and thedark gray region shows the zonewhere sensitizationoccurs.Asterisks andnumber signs
denote statistical significant differences after one-wayANOVAwith the cisplatin-only treatment andwith the cisplatin 317–326 treatment, respectively (n
6 independent experiments). Error bars indicate mean 95% confidence intervals.
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FIGURE 4.Direct interaction of 317–326withDLC1 requires aWXWmotif that is sufficient tomediate the tumor sensitization effect of 317–326.A and
B, effect of increasing doses of 317–319 on U2OS cell migration over time (A) and on sensitization to apoptosis induced by 30 M cisplatin (B) (n  3
independent experiments). Asterisks denote statistical significance after repeated measurement ANOVAs (A). Error bars indicate mean  95% confidence
intervals,C, HEK-293T cellswere transfectedwith the indicated combinations of plasmids. Twomilligramsof cell lysateswere immunoprecipitated (IP) using an
anti-HA antibody. Fortyg of total lysates (TL) were also loaded.Western blotting (WB) against theHA tag (N2) andGFP (DLC1–3)was performed. The cropped
blot is representative of three independent experiments.D, workingmodels. Model 1 suggests that DLC1 andDLC2mediate every 317–326 anticancer effects,
whereasmodel 2 includes a third player thatwouldmediate the effects of 317–326 on apoptosis. E, isothermal titration calorimetrywas used to investigate the
binding between 317–326 and the GAP domain of DLC1. This panel displays the raw data of the heat pulses resulting from titration of the recombinant
GST-DLC1-GAPdomain (50M) in the calorimetric cell with serial injections of 317–326 at a 500M concentration. The lower paneldisplays the integrated heat
pulses (in kcal), normalized per mole of 317–326, as a function of the molar ratio (317–326 concentration/DLC1-GAP concentration). The resulting curve was
fitted to a model equation allowing the determination of the KD. The dissociation constant and the molar ratio displayed here are the mean of three
experiments. F, as controls, the recombinantGST-DLC1-GAPdomainwas titratedwith theRasGAPW317Amutant peptide (upper right) and theRasGAPW319A
mutant peptide (lower right) (n 3 independent experiments).
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The dissociation constant (KD) of the interaction between the
RasGAP 317–326 sequence and the DLC1 GAP domain was
calculated to be 5 M (Fig. 4E, lower panel). This KD is in
agreement with the functional TAT-RasGAP317–326 EC50 val-
ues obtained for apoptosis (5 M), adhesion (11.5 M) and
migration (16.5 M) (Fig. 2D).
We next wanted to determine the binding mode of 317–326
to DLC1. In silico docking experiments of the RasGAP SH3
domain (PDB: 2JO5) to the DLC1 GAP domain (PDB: 3KUQ)
revealed a preferred binding mode involving polar and nonpo-
lar interactions of RasGAPTrp-317 to DLC1 Leu-830 andAsn-
829, as well as a cation- interaction between RasGAPTrp-319
and DLC1 Arg-677 (Fig. 5A). This in silico prediction was in
agreement with the immunoprecipitation assays using DLC1
mutants bearing point mutations at position 677 and at posi-
tions 829 and 830. Fig. 5B (left blot) shows that these mutated
DLC1 proteins have impaired fragment N2 binding abilities.
Conversely, alanine substitutions of Trp-317 and Trp-319 in
fragment N2 greatly reduced its capacity to bind wild-type
DLC1 (Fig. 5B, right blot).
Fig. 5A was derived from the structure of the RasGAP
sequence in its natural L-form. One could question whether the
FIGURE 5. Structural model of RasGAP binding to DLC1. A, in silico docking of DLC1 GAP domain (PDB ID: 3KUQ; in blue) and RasGAP SH3 domain (PDB ID:
2JO5; inorange) interaction. The right paneldisplays the interactionbetween the SH3domainof RasGAPand theGAPdomainofDLC1. This interaction involves
the Trp-317 and Trp-319 residues of RasGAP and the Arg-677, Asn-829, and Leu-830 residues of DLC1. The left panel shows a lowermagnification image of this
interaction. This binding mode had a geometric shape complementarity score of 10024. See Refs. 20 and 21 for score interpretation. The next best binding
mode (not shown) had a score of 9804. The spatially nearest calculated pose (not shown) had a root mean square deviation of 15.1 Å as compared with the
binding mode displayed in the figure and had a geometric shape complementarity score of 9488. B, immunoprecipitation assays displaying the interaction
between wild-type fragment N2 and mutants of DLC1 (left blot) and between wild-type DLC1 and mutants of fragment N2 (right blot). HEK 293T cells were
transfected with the indicated combinations of plasmids. Two milligrams of cell lysates were immunoprecipitated (IP) using an anti-V5 antibody. Forty g of
total lysates (TL) were also loaded. Western blotting (WB) against the HA tag (N2) and the V5 tag (DLC1) was performed. The left blot was cropped, but all the
lanes originate from the same exposure of one given blot. Cropped blots are representative of three independent experiments. C, retro-inversoWMWpeptide
(D-aminoacids) superimposedon the conformationof theWMWresiduesof RasGAP (L-aminoacids). The twopeptides are coloredaccording to theatomtypes.
Lighter colors have been applied to the retro-inverso peptide.
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TAT-RasGAP317–326 peptide, synthesized with D-amino acids,
adopts a similar configuration. To assess this point, we per-
formed an in silico superimposition between the WMW
sequences in D-amino acids and the one derived from the SH3
domain of RasGAP (L-form, PDB ID: 2J05). Fig. 5C shows a
virtual identical structure for both conformations, indicating
that the D-amino acid version of 317–326 is likely to engage
DLC1 as the corresponding natural L-form does.
DISCUSSION
Increasing the rate of death induced by chemotherapy spe-
cifically in cancer cells and impairing their invasiveness are
prime strategies to fight cancer. We previously reported that a
cell-permeable peptide derived from RasGAP, 317–326, had
the ability to act as a dual anticancer peptide by sensitizing
tumor cells to anticancer therapy-induced cell death and by
hampering invasiveness (8, 9, 11). The mode of action of this
peptide is still imprecisely defined. However, recent data dem-
onstrated that the DLC1 tumor suppressor binds to the paren-
tal molecule (fragment N2) that contains 317–326 and that
DLC1 is required for some of the anticancer activities of 317–
326 (11). This new information allowed us to evaluate whether
317–326 is able to bind the DLC1 GAP domain using ITC and
their mode of binding using site-directed mutagenesis and in
silicomodeling approaches. The KD of this interaction is about
10-fold higher than the KD calculated for the interaction
between the SH3 domain of RasGAP with the DLC1 GAP
domain (0.6 M) (31). The weaker binding affinity of 317–326
with the DLC1 GAP domain could be explained by the number
of amino acids involved in the interaction. Indeed, it appears
that only two amino acids are necessary for this binding,
whereas it has been reported that three amino acids are
involved in the interaction between the RasGAP SH3 domain
and the DLC1 GAP domain (31).
In this study, we show that sensitization to apoptosis, migra-
tion, and adhesion was differentially modulated by 317–326
(Fig. 2D) but that this globally required the same crucial amino
acids (Fig. 2C). The full-length RasGAP peptide could be nar-
rowed down to a three-amino acid peptide, 317–319, that still
bears most of the anticancer activities of the longer construct
(Fig. 4, A and B). However, in contrast to its effect on apoptosis
sensitization, the ability of 317–319 to inhibit migration was
reduced as compared with that of the 10 amino acid 317–326
sequence. This suggests that two targets are involved in trans-
ducing the RasGAP peptide anticancer properties. Here, we
show that another DLC isoform, DLC2, is also engaged by frag-
ment N2 (Fig. 4E), raising the possibility that the second target
is DLC2.However, this remains to be demonstrated. It has been
previously reported that the SH3 of RasGAP inhibits the GAP
activity of DLC1 (33). These results have been confirmed very
recently by the observation that RasGAP SH3 domain inhibits
the GAP activity of DLC1 in vitro (31). Therefore, a reasonable
assumption is that 317–319, by engaging the Arg-677 finger of
DLC1, also inhibits the GAP activity of DLC1. However, DLC1
exerts some of its functions in a GAP-independent manner
(29), and it remains possible that 317–326 mediates its effects
by modulating the GAP-independent activities of DLC1. In
favor of this second possibility is our recent observation that
Rho inhibition using the C3 exoenzyme does not prevent 317–
326 from increasing adhesion (11).
We have demonstrated here that the Trp-317 and Trp-319
residues are required for 317–326 to mediate its anticancer
effects. The importance of these residues for protein-protein
interaction is consistent with previously published structural
data showing that Trp-317 and Trp-319 establish a hydropho-
bic pocket allowing the dimerization of the SH3 domain of Ras-
GAP (24). Data collected in the present study suggest that other
amino acids, although not strictly required for the biological
activity of the RasGAP-derived peptide, are nevertheless of
importance, in particular as structural scaffolding residues
(amino acids 323–325). Interestingly, the hydrophilic residues
of 317–326 (Thr-321, Asn-322, and Asp-326), known to be
exposed at the surface of the RasGAP SH3 crystal (24), are dis-
pensable for 317–326-mediated anticancer effects. This sug-
gests that hydrophobicity is a key chemical property through
which 317–326 (and likely the endogenous p120 RasGAP SH3
domain) functions. Met-318, a residue that is not strictly con-
served during evolution but whose hydrophobicity is however
evolutionary conserved (leucine in insects), could be indeed
replaced by a hydrophobic leucine residue without any loss in
activity of 317–326. Another important question is whether a
WaW motif (where a represents an aliphatic residue) can be
found elsewhere within the human proteome and be a putative
target of DLC1/2. Not surprisingly, hundreds of proteins bear
such a motif, but none of them correspond to known DLC-
interacting proteins or are predicted to be involved in biological
functions potentially modulated by the DLC proteins (data not
shown) (29).
The discovery that a very short peptidic motif, consisting of
only two tryptophan amino acids separated by a spacer residue
(WXW), still bears, at least to some extent, the anticancer activ-
ities of the parental molecule provides the basis to undertake
the rational design of small molecules with similar activities.
Such drugs, by potentiating chemotherapy and impinging on
metastatic progression, may be of considerable benefit to can-
cer patients.
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